ASH 2023: Top abstracts in MM and other plasma cell dyscrasias

4

Results of the phase III randomized Iskia trial: Isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients

Francesca Gay

207

Daratumumab, carfilzomib, lenalidomide, and dexamethasone induction and consolidation with tandem transplant in high-risk newly diagnosed myeloma patients: Final results of the phase 2 study IFM 2018-04

Cyrille Touzeau

208

Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed MM: First results of the phase 2 EMN26 study

Niels W.C.J. van de Donk

209

GEM2017FIT trial: Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) Plus/minus daratumumab (D), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: Phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (NDMM) Patients aged between 65 and 80 years

Maria-Victoria Mateos

339

Minimally invasive assessment of measurable residual disease (MRD) in multiple myeloma (MM)

Carmen Gonzalez

340

Mass spectrometry-based assessment of M-Protein in peripheral blood during maintenance therapy in multiple myeloma (MM) in the phase III ATLAS trial

Tadeusz Kubicki

342

Dynamic frailty status enables better prediction of survival probability - results of the HOVON 143 study

Febe Smits

533

Longitudinal screening of mutant hematopoietic progenitor cells (HPC) in multiple myeloma (MM) and its association with secondary primary malignancies (SPM)

Cristina Perez

647

Comparison of response and survival outcomes in standard- and high-risk newly diagnosed transplant-eligible multiple myeloma (NDMM) patients treated with lenalidomide, bortezomib and dexamethasone (RVD) versus daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD)

Nisha S. Joseph

1022

Updated results of a phase I open-label single-arm study of dual targeting BCMA and CD19 fastcar-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma

Juan Du

4762

Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus rvd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (Pts) with newly diagnosed multiple myeloma (NDMM) in the determination phase 3 trial

Jeffrey A. Zonder

LBA-1

Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone (VRd) versus Vrd alone in patients (Pts) with Newly diagnosed multiple myeloma (NDMM) Who are eligible for autologous stem cell transplantation (ASCT): Primary results of the Perseus trial

Pieter Sonneveld

91

Real-world safety and efficacy of teclistamab for patients with heavily pretreated relapsed-refractory multiple myeloma

Danai Dima

219

BMS-986393 (CC-95266), a G protein–coupled receptor class C group 5 member D (GPRC5D)–targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Updated results from a phase 1 study

Susan Bal

338

Venetoclax in combination with daratumumab and dexamethasone elicits deep, durable responses in patients with t(11;14) relapsed/refractory multiple myeloma: Updated analyses of minimal residual disease negativity in phase 1/2 study

Nizar J. Bahlis

761

Efficacy outcomes and characteristics of patients with multiple myeloma (MM) Who achieved sustained minimal residual disease negativity after treatment with equecabtagene autoleucel (Eque-cel, CT103A) in Fumanba-1

Chunrui Li

783

Ixazomib-based consolidation and maintenance prolongs progression-free survival after salvage autologous stem cell transplantation (sASCT): Results from interim analysis of UK-MRA Myeloma XII (ACCoRD)

Gordon Cook

1009

Randomized phase 3 study of pomalidomide cyclophosphamide dexamethasone (PCD) Versus pomalidomide dexamethasone (PD) in relapse or refractory myeloma: An Asian Myeloma Network (AMN) study

Wee-Joo Chng

1010

Efficacy and safety of less frequent/lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study

Ajai Chari

1011

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Hang Quach

1013

Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the CC-92480-MM-002 trial

Paul G. Richardson

1014

Talquetamab + pomalidomide in patients with relapsed/refractory multiple myeloma: Safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study

Jeffrey V. Matous

1021

The phase 2 CARTITUDE-2 trial: Updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B)

Jens Hilengrass

1027

Real world outcomes with idecabtagene vicleucel (Ide-Cel) CAR-T cell therapy for relapsed/refractory multiple myeloma

Surbhi Sidana

1028

Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3

Paula Rodríguez Otero

3377

Updated results of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma with prior exposure to t-cell redirecting therapies: Results of the phase 1/2 MonumenTAL-1 study

Andrzej J. Jakubowiak

3499

Alternative Lymphodepletion strategies lead to similar response rates and toxicities in standard-of-care BCMA-directed CAR-T therapy in relapsed refractory multiple myeloma

Shonali Midha

210

Efficacy and safety of daratumumab (DARA) monotherapy in patients with intermediate-risk or high-risk smoldering multiple myeloma (SMM): Final analysis of the phase 2 Centaurus study

Ola Landgren

530

Predicting an underlying clonal plasma cell population in light-chain monoclonal gammopathy of undetermined significance using free light-chain ratio

Jon Thorir Oskarsson

539

Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3B light-chain amyloidosis: A phase 2 study by the European Myeloma Network

Efstathios Kastritis

542

Real-world treatment patterns and clinical outcomes among triple-class exposed and b-cell maturation antigen (BCMA) exposed multiple myeloma patients

Hira Mian

645

Isolated and dynamic peripheral blood residual disease status characterized by mass spectrometry predicts outcome in patients with high risk smoldering multiple myeloma treated in the GEM-CESAR trial

Noemi Puig

754

Exploiting the gut microbiota to boost immunotherapy and switch the trajectory of multiple myeloma

Laura Lucia Cogrossi

3346

Renal Failure in Patients with Newly Diagnosed Multiple Myeloma Eligible for Autologous Stem Cell Transplant in LATAM - on behalf of Gelamm

Humberto Martinez-Cordero

3352

Survival of patients with multiple myeloma treated with bortezomib-based triplets and autologous hematopoietic stem cell transplant as first line in Latin America

Eloisa Riva

3325

Impact of 1q21 gain and amplification on daratumumab-treated multiple myeloma patients: Real-world data from the Australia-New Zealand and Asia-Pacific myeloma and related diseases registries

Kenneth J C Lim

2019

Isatuximab rescue for inadequate response to lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: Primary analysis of the phase II Iril study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Slavisa Ninkovic

2225

Comparison of various stem cell mobilization regimens for multiple myeloma: A 15-year retrospective institutional analysis from India

Sumeet Mirgh

4845

Three-year follow-up on efficacy and safety results from phase 1 Lummicar study 1 of zevorcabtagene autoleucel in Chinese patients with relapsed or refractory multiple myeloma

Chengcheng Fu

1981

Update analysis of central nervous system multiple myeloma prognosis and survival: A real-world multi-institutional study of the Greek Myeloma Study Group

Eirini Katodritou

2020

Low-dose venetoclax-dexamethasone in t(11;14) positive relapsed and refractory multiple myeloma; interim results from the ongoing, Danish, investigator-initiated, open label, phase 2 Victoria study

Agoston Gyula Szabo

4696

Risk of Infections in multiple myeloma in the era of novel agents, a population-based study based on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry

Cecilie Hveding Blimark

4729

Upfront autologous stem cell transplantation in myeloma patients >65 years: A population-based study from the Nordic Myeloma Study Group

Kari Lenita Falck Moore

4734

Bortezomib-cyclophosphamide-dexamethasone (VCD) vs bortezomib-lenalidomide-dexamethasone (VRD) in newly diagnosed multiple myeloma: A matched real-world analysis from the Balkan Myeloma Study Group (BMSG)

Efstathios Kastritis

4973

Autologous stem cell transplantation for multiple myeloma in Algeria

Malek Benakli